Sunshine Act

By Elio Evangelista, Director of Research The United States is still waiting for the Centers for Medicare and Medicaid Services (CMS) to issue its final ruling on how it will implement the disclosure rules outlined in the Physician Payments Sunshine...

Six Tips to Help Build the Ideal Thought Leader Database As the industry awaits the release of the delayed Sunshine Act guidelines, pharmaceutical and medical device companies are benefiting from the extra time by reviewing current physician payment reporting...

New study provides process for calculating compliant fair-market value payments Although 100 percent of drug companies compensate key opinion leaders (KOLs) for their method of travel, only 60 percent do so for any preliminary work. And as mandatory public...

By Elio Evangelista,Director of Research In about five weeks, pharmaceutical, biotechnology and medical device companies will have to start compiling and aggregating data on their physician expenditures to meet the requirements spelled out in the Physician...

By Ryan McGuire,Senior Research Analyst A study published in the British Medical Journal has received a lot of attention lately. It highlighted the prevalence of financial conflicts of interest (COI) for researchers sitting on 14 specific guideline-setting...

The sunshine provision of the landmark U.S. healthcare law passed in 2010 requires that drug and device manufacturers report all gifts and payments exceeding $10 in value. While the law seems clear for consulting fees, it becomes quite murky when discussing clinical...

As compliance and medical affairs teams prepare for the Sunshine Act, they are relying less on exact compensation limits for key opinion leaders.  “KOL Fair-Market Value and Aggregate Spend: Documentation, Tracking and the Sunshine Act” found that only 35...

Cutting Edge Information’s new research on European fair-market value benchmarks found that drug manufacturers spend between €153 and €283 for a typical key opinion leader (KOL) engagement. Payments vary by company size; biotechnology companies pay European...

Average physician fee schedules for hourly payments to KOLs have fallen each year since 2006, finds Cutting Edge Information Drug and device manufacturers have responded to criticism over physician payments by decreasing their average level of compensation by...

Although the Sunshine Act requires disclosures for grants and other funding of medical research, the majority of payment categories are focused on promotional engagements. A new report from Cutting Edge Information finds that drug manufacturers are feeling the...